December 9, 2005
The Food and Drug Administration has approved the hepatitis C treatment Ribasphere, co-manufactured by Par Pharmaceutical Cos. and Three Rivers Pharmaceuticals LLC, the companies said Monday. FDA approved Ribasphere, which uses the active ingredient ribavirin, in 200 mg, 400 mg and 600 mg tablets for use with interferon alfa-2a to treat hepatitis C.
|Gene Therapy in HIV Cure Research|
|Making HIV -- and Bias -- 'Part of the Party' to Strengthen Our Response to the Epidemic|
|One Doc's Advice for Caring for Elderly Patients With HIV|
|Bias Is Everywhere: Uncovering HIV Prejudice to Improve Service Delivery|
|Who Tends to Gain Weight With HIV Treatment?|